Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in a proof-of-concept clinical trial ...
Oral presentation characterizes promising PK/PD properties of KP104 in relevant animal models and supports its further development as a potent bifunctional complement inhibitor suitable for both ...
Image of blood cells. KP104 is a bifunctional, first-in-class biologic that works by selectively inhibiting the alternative and terminal pathways in the complement system. The Food and Drug ...
Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...
Current treatment methods for C3 glomerulopathy (C3G) help support kidney function and suppress immune system activity. Emerging therapies interrupt the proteins responsible for disease activity. C3G ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback